45 related articles for article (PubMed ID: 8441174)
1. Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis.
Saxne T; Lecander I; Geborek P
J Rheumatol; 1993 Jan; 20(1):91-6. PubMed ID: 8441174
[TBL] [Abstract][Full Text] [Related]
2. Placental and decidual u-PA, t-PA, PAI-1 and PAI-2 concentrations, as affected by cervical dilatation with laminaria tents or Hegar dilators.
Jonasson A; Larsson B; Lecander I; Astedt B
Thromb Res; 1989 Jan; 53(2):91-7. PubMed ID: 2493685
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of Cardiovascular Risk in Patients With Rheumatoid Arthritis: Results From the TARGET Trial.
Solomon DH; Demler O; Rist PM; Santacroce L; Tawakol A; Giles JT; Liao KP; Bathon JM
J Am Heart Assoc; 2024 Mar; 13(5):e032095. PubMed ID: 38416140
[TBL] [Abstract][Full Text] [Related]
4. The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets.
Buckley BJ; Ali U; Kelso MJ; Ranson M
Curr Drug Targets; 2019; 20(9):970-981. PubMed ID: 30516104
[TBL] [Abstract][Full Text] [Related]
5. Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells.
Thornton S; Raghu H; Cruz C; Frederick MD; Palumbo JS; Mullins ES; Almholt K; Usher PA; Flick MJ
Blood Adv; 2017 Mar; 1(9):545-556. PubMed ID: 29296974
[TBL] [Abstract][Full Text] [Related]
6. A suppressive effect of prostaglandin E
Masuko K; Murata M; Suematsu N; Okamoto K; Yudoh K; Shimizu H; Beppu M; Nakamura H; Kato T
Open Access Rheumatol; 2009; 1():9-15. PubMed ID: 27789978
[TBL] [Abstract][Full Text] [Related]
7. Identification of a specific haptoglobin C-terminal fragment in arthritic synovial fluid and its effect on interleukin-6 expression.
Park HJ; Oh MK; Kim NH; Cho ML; Kim IS
Immunology; 2013 Sep; 140(1):133-41. PubMed ID: 23701120
[TBL] [Abstract][Full Text] [Related]
8. Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors.
Dimitroulas T; Douglas KM; Panoulas VF; Toms T; Smith JP; Treharne GJ; Nightingale P; Hodson J; Kitas GD
Clin Rheumatol; 2013 Sep; 32(9):1357-64. PubMed ID: 23673438
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolysis is down-regulated in mouse collagen-induced arthritis, but its normalization does not alleviate the course of disease.
Kwieciński J; Josefsson E; Jin T
Inflamm Res; 2011 Nov; 60(11):1021-9. PubMed ID: 21786185
[TBL] [Abstract][Full Text] [Related]
10. High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis.
Gobezie R; Kho A; Krastins B; Sarracino DA; Thornhill TS; Chase M; Millett PJ; Lee DM
Arthritis Res Ther; 2007; 9(2):R36. PubMed ID: 17407561
[TBL] [Abstract][Full Text] [Related]
11. Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study.
Rodriguez-Lopez J; Perez-Pampin E; Gomez-Reino JJ; Gonzalez A
Arthritis Res Ther; 2006; 8(1):R1. PubMed ID: 16356191
[TBL] [Abstract][Full Text] [Related]
12. The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.
Li J; Ny A; Leonardsson G; Nandakumar KS; Holmdahl R; Ny T
Am J Pathol; 2005 Mar; 166(3):783-92. PubMed ID: 15743790
[TBL] [Abstract][Full Text] [Related]
13. Discrepancy between mRNA and protein expression of tumour suppressor maspin in synovial tissue may contribute to synovial hyperplasia in rheumatoid arthritis.
Schedel J; Distler O; Woenckhaus M; Gay RE; Simmen B; Michel BA; Müller-Ladner U; Gay S
Ann Rheum Dis; 2004 Oct; 63(10):1205-11. PubMed ID: 15361372
[TBL] [Abstract][Full Text] [Related]
14. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.
Slot O; Brünner N; Locht H; Oxholm P; Stephens RW
Ann Rheum Dis; 1999 Aug; 58(8):488-92. PubMed ID: 10419867
[TBL] [Abstract][Full Text] [Related]
15. Exacerbation of antigen-induced arthritis in urokinase-deficient mice.
Busso N; Péclat V; Van Ness K; Kolodziesczyk E; Degen J; Bugge T; So A
J Clin Invest; 1998 Jul; 102(1):41-50. PubMed ID: 9649555
[TBL] [Abstract][Full Text] [Related]
16. Urokinase in rheumatoid arthritis: causal or coincidental?
Busso N; So A
Ann Rheum Dis; 1997 Dec; 56(12):705-6. PubMed ID: 9496148
[No Abstract] [Full Text] [Related]
17. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints.
Busso N; Péclat V; So A; Sappino AP
Ann Rheum Dis; 1997 Sep; 56(9):550-7. PubMed ID: 9370880
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues.
Szekanecz Z; Haines GK; Koch AE
J Clin Pathol; 1997 Apr; 50(4):314-9. PubMed ID: 9215148
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees.
Belcher C; Fawthrop F; Bunning R; Doherty M
Ann Rheum Dis; 1996 Apr; 55(4):230-6. PubMed ID: 8733439
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-1 beta, plasminogen activator and inhibitor of plasminogen activator in synovial fluid of rheumatoid arthritis, psoriatic arthritis and osteoarthritis.
Pianon M; Punzi L; Stefani MP; Bertazzolo N; Michelotto M; Finco B; Gambari PF
Agents Actions; 1994 Mar; 41(1-2):88-9. PubMed ID: 8079828
[No Abstract] [Full Text] [Related]
[Next] [New Search]
